Company intelligence / Profile preview

CAGE Technologies

San Carlos, California, United Statescagetechnologies.co.uk ↗

Ownership: Private
Development stage: Other

Overview

CAGE Bio is a clinical-stage biotech company developing topical therapies for dermatology, inflammation, and immunology using its proprietary deep eutectic ionic liquid technology. Its lead asset, CGB-500 (topical tofacitinib), is in a Phase 2b trial for moderate to severe atopic dermatitis. Another candidate targeting papulopustular rosacea has advanced to Phase 2.

Therapeutic areas: Dermatology
Modalities: Small moleculeProteinNucleic acid
Industry: Biotech

Partnerships

Not specifically disclosed; R&D partnerships mentioned

Beyond the preview

Go deeper on CAGE Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAGE Technologies.

Explore the full profile